Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
The resistance to immune checkpoint inhibitors (ICIs) presents a significant challenge in enhancing the survival rates of patients with advanced cancer.
Exosomal programmed death-ligand 1 (PD-L1) has become an increasingly important area of research in the context of primary resistance mechanisms of ICIs. This focus is crucial for developing strategies to overcome resistance.
Beyond the well-documented effects of antibiotics and steroids, the influence of other concomitant medications on the efficacy of ICIs has…